Individuals with early-stage diffuse large B-cell lymphoma had an insignificantly higher likelihood of developing secondary primary malignancies after a median follow-up of 13.3 years, and increased odds of developing breast, colorectal, pancreatic and prostate SPMs during the first five years post-diagnosis, compared with those with advanced stage DLBCL, researchers reported in the journal Cancer. However, the findings showed that hematologic SPMs were more likely among those with advanced DLBCL at 10 to 15 years post-diagnosis, while SPMs were associated with significantly higher mortality risk, regardless of disease stage at diagnosis.
DLBCL staging may affect risk of secondary primary malignancies
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.